Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

(2022) Chau Dang et al.   Cancers

An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms

(2022) Hongjuan Yao et al.   Nature Communications

HER2 expression in urothelial carcinoma, a systematic literature review

(2022) Emilie Scherrer et al.   Frontiers in Oncology

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

(2022) Xiangming Fang et al.   Frontiers in Oncology

Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis

(2021) Wei Xu et al.   PLoS One

Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

(2021) Eiji Iwama et al.   EUROPEAN JOURNAL OF CANCER

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

(2020) Zi-Yan Yang et al.   Biology Open

Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report

(2020) Qi Jiang et al.   World Journal of Clinical Cases

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

(2020) Xue‐Wu Wei et al.   Thoracic Cancer

Relationships among cigarette smoking, urinary biomarkers, and urothelial carcinoma risk: a case-control study

(2020) Chi-Jung Chung et al.   ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

(2020) Morgan Rouprêt et al.   EUROPEAN UROLOGY

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers

(2019) Janakiraman Subramanian et al.   ONCOLOGIST

Renal Pelvis Urothelial Carcinoma With Bowel Metastases

(2019) Alex Cheen Hoe Khoo et al.   CLINICAL NUCLEAR MEDICINE

A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics

(2018) C. Sidhanth et al.   Biochemistry and Cell Biology

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

(2016) Francesco Soria et al.   WORLD JOURNAL OF UROLOGY

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers

(2015) Wenhsiang Wen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis

(2015) Andrew W. Hahn et al.   Journal of the National Comprehensive Cancer Network

Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin

(2014) J. Chmielecki et al.   ONCOLOGIST

The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development

(2013) Joel J. Gagnier et al.   HEADACHE

Epidemiology and Risk Factors of Urothelial Bladder Cancer

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

(2011) Anastasia Constantinidou et al.   BREAST

Smad4 Inactivation Promotes Malignancy and Drug Resistance of Colon Cancer

(2011) P. Papageorgis et al.   CANCER RESEARCH

Treatment of HER2-overexpressing breast cancer

(2010) J. Baselga   ANNALS OF ONCOLOGY